- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Most impactful areas to clinical real-world evidence as of 2018
Most impactful areas to clinical real-world evidence as of 2018
Percentage of executives that said select areas would be most impactful to current and future real-world evidence (RWE) as of 2018*
by Matej Mikulic,
last edited
Feb 26, 2019
This statistic depicts the percentage of executives that selected current and projected areas of most impact to real-world evidence (RWE) in clinical trials, as of 2018. According to the source, 60 percent of executives said that a better understanding of subpopulations and heterogeneity of treatment effects would be most impactful to current real-world evidence.
Percentage of executives that said select areas would be most impactful to current and future real-world evidence (RWE) as of 2018*
Loading statistic...
Expand statistic
| Current | Future | |
|---|---|---|
| Better understanding subpopulations and heterogeneity of treatment effects | 60% | 40% |
| Understanding burdern of disease | 60% | 5% |
| Monitoring patient safety (i.e., pharmacovigilance) | 50% | 30% |
| Comparative effectiveness research | 35% | 20% |
| Supporting regulatory submission and or label expansion | 20% | 45% |
| Accelerating the execution of clinical trials using RWD as a control arm for clinical trials | 15% | 35% |
| Optimizing the design of clinical trials | 10% | 50% |
| Identifying new drug targets/areas of unmet needs | 10% | 20% |
| Design of value-based contracting schemes | 5% | 40% |
| Biomarker hypothesis generation/validation | 10% | 10% |
| Supporting patient engagement programs | 0% | 5% |
| Measuring sales performance, targeting, and marketing metrics | 0% | 0% |
| Informing business development and portfolio strategy (therapeutic area assessment) | 0% | 0% |
| Informing pricing strategies | 0% | 0% |
| Current | Future | |
|---|---|---|
| Better understanding subpopulations and heterogeneity of treatment effects | 60% | 40% |
| Understanding burdern of disease | 60% | 5% |
| Monitoring patient safety (i.e., pharmacovigilance) | 50% | 30% |
| Comparative effectiveness research | 35% | 20% |
| Supporting regulatory submission and or label expansion | 20% | 45% |
| Accelerating the execution of clinical trials using RWD as a control arm for clinical trials | 15% | 35% |
| Optimizing the design of clinical trials | 10% | 50% |
| Identifying new drug targets/areas of unmet needs | 10% | 20% |
| Design of value-based contracting schemes | 5% | 40% |
| Biomarker hypothesis generation/validation | 10% | 10% |
| Supporting patient engagement programs | 0% | 5% |
| Measuring sales performance, targeting, and marketing metrics | 0% | 0% |
| Informing business development and portfolio strategy (therapeutic area assessment) | 0% | 0% |
| Informing pricing strategies | 0% | 0% |
Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Register now
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Feb 26, 2019
This statistic depicts the percentage of executives that selected current and projected areas of most impact to real-world evidence (RWE) in clinical trials, as of 2018. According to the source, 60 percent of executives said that a better understanding of subpopulations and heterogeneity of treatment effects would be most impactful to current real-world evidence.
- Show sources information
- Show publisher information
- Release date
- January 2019
- Region
- Worldwide
- Survey time period
- as of 2018
- Supplementary notes
- * The figures denote current and future application areas ranked among the top three by respondents and expressed as a percentage.
Source
- Show sources information
- Show publisher information
- Release date
- January 2019
More information
- Region
- Worldwide
- Survey time period
- as of 2018
- Supplementary notes
- * The figures denote current and future application areas ranked among the top three by respondents and expressed as a percentage.
Other statistics on the topic
+Pharmaceutical Products & Market
Total global pharmaceutical R&D spending 2010-2024
Pharmaceutical Products & Market
Research and development expenditure: U.S. pharmaceutical industry 1995-2018
+Pharmaceutical Products & Market
Leading global contract research organizations based on revenue 2017
+Pharmaceutical Products & Market
Total number of registered clinical studies worldwide since 2000
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Clinical trials"
- R&D overview
The most important statistics
- Total global spending on pharmaceutical research and development from 2010 to 2024 (in billion U.S. dollars)Total global pharmaceutical R&D spending 2010-2024
- Percentage of spending on research and development of total revenue from 2013 to 2017, by industrial sector*Industry sectors - expenditure on research and development 2013-2017
- Selected top pharmaceutical R&D projects based on net present value (NPV) as of May 2019 (in million U.S. dollars)Top pharmaceutical R&D projects based on net present value May 2019
- Research and development expenditure of total U.S. pharmaceutical industry from 1995 to 2018 (in billion U.S. dollars)*Research and development expenditure: U.S. pharmaceutical industry 1995-2018
- Pharmaceutical research and development spending in selected European countries in 2017 (in million euros)Research and development in European pharmaceutical industry by country 2017
- Total clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2020 (in million U.S. dollars)Total clinical research funding by National Institutes for Health 2013-2020
- Top R&D companies
The most important statistics
- Global top 10 pharmaceutical companies based on projected R&D spending in 2024 (in billion U.S. dollars)Global top pharmaceutical companies based on R&D spending 2024
- World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018*Top 50 global pharmaceutical and biotech companies by R&D intensity in 2017/2018
- World's top 50 pharmaceutical and biotechnology companies based on R&D spending growth in 2017/2018Top pharmaceutical companies in R&D spending growth 2017-2018
- Number of patients who took part in clinical trials for pharmaceutical company Roche from 2009 to 2017*Roche: participation of patients in clinical trials 2009-2017
- Top global contract research organizations (CROs) based on 2017 revenue (in million U.S. dollars)Leading global contract research organizations based on revenue 2017
- Clinical studies
The most important statistics
- Complexity of clinical trials compared in 2001-2005 and 2011-2015Comparison between the complexity of clinical trials 2001-2015
- Increase in clinical trials' complexity between 2001-2005 and 2011-2015Increase in clinical trials' complexity 2001-2015
- Number of registered clinical studies worldwide by location as of October 2019Number of registered clinical studies by location worldwide 2019
- Percentage of registered clinical studies worldwide by location as of October 2019Percent of registered clinical studies worldwide by location 2019
- Percentage of registered recruiting clinical studies worldwide by location as of October 2019Share of recruiting clinical studies worldwide by location 2019
- Total number of registered clinical studies worldwide since 2000 (as of October 2019)*Total number of registered clinical studies worldwide since 2000
- Total number of registered clinical studies with posted results worldwide since 2009 (as of October 2019)*Total number of registered clinical studies with posted results worldwide 2009-2019
- Participation
The most important statistics
- Percentage of population enrolled in clinical trials in selected countries worldwide as of 2016Clinical trial enrollment by select country and region 2016
- Top 20 countries by number of clinical trial participants in 2015-2016Top clinical trial participant countries 2015-2016, by number
- Top 20 clinical trial participant countries worldwide in 2015-2016, by share of participants (in percentage)Top clinical trial participant countries worldwide 2015-16, by share
- Number of clinical trial participants in the U.S. and rest of the world in 2016, by therapeutic areaClinical trial participants U.S. vs. rest of world by therapy area 2016
- Gender share of clinical trial participants worldwide in 2015-2016, by geographic locationClinical trial participants gender share worldwide 2015-16, by geographic location
- Ethnicity share of clinical trial participants worldwide in 2015-2016, by geographic location (in percentage)Clinical trial participants ethnicity share worldwide 2015-16, by geographic location
- Costs and market
The most important statistics
- Cost of developing a drug in the U.S. from the 1970s until today (in million U.S. dollars)*Pharmaceuticals: cost of drug development in the U.S. since 1975
- Total R&D costs for selected cancer drugs on the market as of 2017 (in million U.S. dollars)Total R&D costs of select cancer drugs 2017
- Market share of clinical trials worldwide by segment as of 2016Market share of clinical trials worldwide by segment
- Clinical contract research organization (CRO) market worldwide from 2011 to 2020 (in billion U.S. dollars)Clinical CRO market size worldwide 2011-2020
- Size of the U.S. market for healthcare contract research outsourcing (CRO) from 2016 to 2022, by type (in million U.S. dollars)Size of U.S. healthcare CRO market 2016-2022 by type
- Size of the total U.S. clinical trial supplies market from 2016 to 2025 (in million U.S. dollars)Size of total U.S. clinical trial supplies market 2016-2025
- Success rates
The most important statistics
- Probability of success for drugs in the U.S. in different development phases between 2006 and 2015U.S. drug development phase success rates 2006-2015
- Probability of Phase II success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase II success rates 2006-2015, by disease area
- The probability of Phase III success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase III success rates from 2006 to 2015, by disease area
- Probability of success for oncology vs non-oncology drugs in the U.S. in the different development phases from 2006 to 2015U.S. development Phase success rates for oncology and non oncology drugs 2006-2015
- Probability of success for new drugs in the U.S. by development phase between 2006 and 2015, by drug classification U.S. drug development Phase success rates, by drug classification 2006-2015
- Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015U.S. development phase success rates for drugs with and without biomarkers 2006-2015
- Approvals, launches, setbacks
The most important statistics
- Number of new chemical or biological entities developed between 1992 and 2018, by region of originPharmaceutical industry - number of new substances 1992-2018
- Total number of novel drugs approved by CDER from 2008 to 2018Number of novel drugs approved annually by CDER 2008-2018
- Percentage of drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) in 2018 that met select key measurementsKey measurements of U.S. CDER drug approvals in 2018
- Number of first premarket approvals (PMA/HDE) granted by the FDA for medtech products from 2005 to 2018FDA first premarket approvals for medtech products granted 2005-2018
- Top biotech and pharma product launches in 2018 and revenue forecast for 2022 (in million U.S. dollars)Projection of top 2018 pharma and biotech launches by revenue 2022
- Number of unsuccessful Alzheimer’s drugs in development in the U.S. from 1998 to 2017Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2017
- Unsuccessful attempts and new drugs for select cancer types between 1998 and 2014Unsuccessful attempts and new drugs for cancer types 1998-2014
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: You might find this interesting as well
Statistics
- Presumed benefits of participation in clinical trials among adults worldwide in 2017
- Type 2 diabetes clinical trial success rates U.S. 2006-2015, by phase and indication
- Number of clinical trials for new drugs in South Korea 2008-2017
- U.S. addiction medication clinical trials in 2018, by phase and indication
- Novel pain drug clinical trials success rates U.S. 2006-2015, by phase
- Clinical trial starts for new obesity drugs U.S. 2008-2017
- U.S. abuse deterrent pain medication clinical trial starts 2006-2016, by phase
- U.S. innovative pain medication clinical trial starts 2006-2016, by phase
- Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
- Proportion of medicines that must be tested according to adults worldwide in 2017
- Clinical trial participants woman share worldwide 2015-16, by country
- Obesity clinical trial success rates for novel drugs U.S. 2006-2015 by phase
- U.S. pain medication clinical pipeline 2017, by type and phase
- U.S. pain medication clinical pipeline in 2017, by phase and indication
- Clinical trials starts for new type 2 diabetes drugs U.S. 2008-2017
- Clinical trial referral sources globally as of 2017
- Adults globally that understood what a clinical trial is as of 2017, by participation
- Obesity drugs clinical pipeline U.S. 2018, by type and phase
- Clinical trial sites by country development status from 2006 to 2012
- Number of active clinical trials and studies in Australia by therapeutic class 2014
Statistics on "Clinical trials - R&D overview"
- Total global pharmaceutical R&D spending 2010-2024
- Industry sectors - expenditure on research and development 2013-2017
- Top pharmaceutical R&D projects based on net present value May 2019
- Research and development expenditure: U.S. pharmaceutical industry 1995-2018
- Research and development in European pharmaceutical industry by country 2017
- Total clinical research funding by National Institutes for Health 2013-2020
Statistics on "Clinical trials - Top R&D companies"
- Global top pharmaceutical companies based on R&D spending 2024
- Top 50 global pharmaceutical and biotech companies by R&D intensity in 2017/2018
- Top pharmaceutical companies in R&D spending growth 2017-2018
- Roche: participation of patients in clinical trials 2009-2017
- Leading global contract research organizations based on revenue 2017
Statistics on "Clinical trials - Clinical studies"
- Comparison between the complexity of clinical trials 2001-2015
- Increase in clinical trials' complexity 2001-2015
- Number of registered clinical studies by location worldwide 2019
- Percent of registered clinical studies worldwide by location 2019
- Share of recruiting clinical studies worldwide by location 2019
- Total number of registered clinical studies worldwide since 2000
- Total number of registered clinical studies with posted results worldwide 2009-2019
Statistics on "Clinical trials - Participation"
- Clinical trial enrollment by select country and region 2016
- Top clinical trial participant countries 2015-2016, by number
- Top clinical trial participant countries worldwide 2015-16, by share
- Clinical trial participants U.S. vs. rest of world by therapy area 2016
- Clinical trial participants gender share worldwide 2015-16, by geographic location
- Clinical trial participants ethnicity share worldwide 2015-16, by geographic location
Statistics on "Clinical trials - Costs and market"
- Pharmaceuticals: cost of drug development in the U.S. since 1975
- Total R&D costs of select cancer drugs 2017
- Market share of clinical trials worldwide by segment
- Clinical CRO market size worldwide 2011-2020
- Size of U.S. healthcare CRO market 2016-2022 by type
- Size of total U.S. clinical trial supplies market 2016-2025
Statistics on "Clinical trials - Success rates"
- U.S. drug development phase success rates 2006-2015
- U.S. drug development Phase II success rates 2006-2015, by disease area
- U.S. drug development Phase III success rates from 2006 to 2015, by disease area
- U.S. development Phase success rates for oncology and non oncology drugs 2006-2015
- U.S. drug development Phase success rates, by drug classification 2006-2015
- U.S. development phase success rates for drugs with and without biomarkers 2006-2015
Statistics on "Clinical trials - Approvals, launches, setbacks"
- Pharmaceutical industry - number of new substances 1992-2018
- Number of novel drugs approved annually by CDER 2008-2018
- Key measurements of U.S. CDER drug approvals in 2018
- FDA first premarket approvals for medtech products granted 2005-2018
- Projection of top 2018 pharma and biotech launches by revenue 2022
- Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2017
- Unsuccessful attempts and new drugs for cancer types 1998-2014
Further related statistics
- Presumed benefits of participation in clinical trials among adults worldwide in 2017
- Type 2 diabetes clinical trial success rates U.S. 2006-2015, by phase and indication
- Number of clinical trials for new drugs in South Korea 2008-2017
- U.S. addiction medication clinical trials in 2018, by phase and indication
- Novel pain drug clinical trials success rates U.S. 2006-2015, by phase
- Clinical trial starts for new obesity drugs U.S. 2008-2017
- U.S. abuse deterrent pain medication clinical trial starts 2006-2016, by phase
- U.S. innovative pain medication clinical trial starts 2006-2016, by phase
- Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
- Proportion of medicines that must be tested according to adults worldwide in 2017
- Clinical trial participants woman share worldwide 2015-16, by country
- Obesity clinical trial success rates for novel drugs U.S. 2006-2015 by phase
- U.S. pain medication clinical pipeline 2017, by type and phase
- U.S. pain medication clinical pipeline in 2017, by phase and indication
- Clinical trials starts for new type 2 diabetes drugs U.S. 2008-2017
- Clinical trial referral sources globally as of 2017
- Adults globally that understood what a clinical trial is as of 2017, by participation
- Obesity drugs clinical pipeline U.S. 2018, by type and phase
- Clinical trial sites by country development status from 2006 to 2012
- Number of active clinical trials and studies in Australia by therapeutic class 2014
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Please log in to access our additional functions
Register in seconds and access exclusive features.
Basic Account
|
Instant Access
Premium Account
| ||
|---|---|---|---|
Our services
Click the question mark for further information | Free |
$59 per month*
| |
| Basic statistics | |||
| Premium statistics | |||
|
Graph download
| |||
| Download PDF | |||
|
Excel download
| |||
| Register | Purchase now | ||
*Duration: 12 months, billed annually, single license
Yes, let me download!
...and make my research life easier.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.